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Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade
cAMP and underpin the compartmentalization of cAMP signaling
through their targeting to particular protein complexes and
intracellular locales. We describe the discovery and characteriza-
tion of a small-molecule compound that allosterically activates
PDE4 long isoforms. This PDE4-specific activator displays reversible,
noncompetitive kinetics of activation (increased Vmaxwith unchanged
Km), phenocopies the ability of protein kinase A (PKA) to activate
PDE4 long isoforms endogenously, and requires a dimeric enzyme
assembly, as adopted by long, but not by short (monomeric),
PDE4 isoforms. Abnormally elevated levels of cAMP provide a critical
driver of the underpinning molecular pathology of autosomal domi-
nant polycystic kidney disease (ADPKD) by promoting cyst formation
that, ultimately, culminates in renal failure. Using both animal and
human cell models of ADPKD, including ADPKD patient-derived pri-
mary cell cultures, we demonstrate that treatment with the prototyp-
ical PDE4 activator compound lowers intracellular cAMP levels,
restrains cAMP-mediated signaling events, and profoundly inhibits
cyst formation. PDE4 activator compounds thus have potential as
therapeutics for treating disease driven by elevated cAMP signal-
ing as well as providing a tool for evaluating the action of long
PDE4 isoforms in regulating cAMP-mediated cellular processes.
PDE4 | PDE4 activator | cyclic AMP | ADPKD | phosphodiesterase
Cyclic AMP (cAMP) is a pivotal and ubiquitous second mes-senger that controls the functioning of a wide spectrum of
key biological processes. The functional attributes of cAMP are
mediated by distinct effector systems; namely, the archetypal
signaling system provided by protein kinase A (PKA) (1) to-
gether with the more recently discovered systems provided by
exchange factor activated by cAMP (Epac) (2, 3) and the so-
called POPEYE proteins (4). cAMP homeostasis is effected by
an interplay of synthesis, determined by members of a multigene
family of adenylyl cyclases, and degradation, via a multigene
family of cyclic nucleotide phosphodiesterases (PDEs) (5–7).
Of particular importance in this are isoforms of the four-gene
(A/B/C/D) cAMP phosphodiesterase-4 (PDE4) family. The use
of PDE4-selective inhibitors, PDE4 gene-knockout studies,
dominant-negative approaches, and genetic analyses have iden-
tified the cAMP-specific PDE4 family as playing a pivotal role in
regulating a wide variety of key physiological processes and in
underpinning the molecular pathology of various diseases (8–
12). The therapeutic potential of manipulating PDE4 activity is
clearly demonstrated by selective inhibitors acting as antiin-
flammatory agents and recently adopted for clinical use in the
treatment of psoriasis, psoriatic arthritis, and chronic obstructive
pulmonary disease (COPD) (5, 13–15).
PDE4 isoform heterogeneity allows for their differential reg-
ulation through cross-talk and feedback processes together with
a distinct critical spatial component, achieved by targeting of
isoforms to specific cellular signaling complexes (8). In this way,
targeted degradation by spatially discrete PDE4 isoforms plays a
major role in underpinning the compartmentalization of in-
tracellular cAMP signal transduction by forming and shaping
intracellular pools/gradients of cAMP that are able to modulate
distinct cellular processes (8).
PDE4 isoforms are grouped into four categories. These are
long isoforms, which possess both of the regulatory upstream
conserved region 1 (UCR1) and upstream conserved region 2
(UCR2) domains; short forms, which lack UCR1; supershort
forms, which both lack UCR1 and have a truncated UCR2; and
dead-short forms, which lack both UCR1 and UCR2 as well as
have a truncated catalytic unit that renders them catalytically
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inactive (9, 12). These various UCR1/2 combinations confer
distinct differences in the ability of PDE4 isoforms to be regu-
lated by phosphorylation through the action of a variety of protein
kinases, allowing PDE4 isoforms to serve as key nodes for in-
tegrating responses between different signaling pathways (8, 16).
In particular, UCR1-targeted phosphorylation, with concomitant
activation, of PDE4 long isoforms by PKA provides a pivotal
component of the cellular cAMP signaling desensitization system
(17). Such functionality requires only a relatively small increase
(∼30–100% range) in the cAMP degrading activity of PDE4 long
isoforms to exert a profound effect on diminishing cellular cAMP
levels (17–19). Furthermore, MK2 [MAP kinase-activated protein
kinase 2 (MAPKAPK2)], the key downstream kinase of the p38
MAP kinase inflammatory pathway, also phosphorylates PDE4 long
isoforms, thereby achieving subtle inhibitory manipulation of the
level of activation of PDE4 long isoforms conferred by PKA
phosphorylation (18).
Interestingly, PDE4 long isoforms, but not short isoforms, show
similar levels of activation in response to the binding of phospha-
tidic acid to UCR1 (20) and the binding of a short “UCR1-related”
peptide (UCR1C), which has been suggested to function by dis-
rupting the interaction between the UCR1 and UCR2 (21). Thus,
long, but not short, isoforms from all four PDE4 subfamilies have
an inherent ability to be activated endogenously through a variety of
routes. Such activation appears to involve the UCR1 regulatory
domain and requires the enzyme to adopt a dimeric conformation
(22). This particular quaternary structural status is uniquely asso-
ciated with long PDE4 isoforms because two key dimerization in-
terfaces are involved, one located within the catalytic domain and
the other involving the long-form–specific UCR1 domain (23).
Here, we describe a drug-like compound that allosterically acti-
vates long, but not short, PDE4 isoforms. This PDE4-selective long-
isoform activator demonstrably lowers intracellular cAMP levels
leading to reduced PKA activity. Compounds exerting such func-
tional effects may have utility in treating diseases where chronically
elevated cAMP levels drive the molecular pathology. Indeed, using
in vitro kidney cell models of one such disease, namely autosomal
dominant polycystic kidney disease (ADPKD), where chronically
elevated cAMP levels drive cyst formation (24–28), we show that
the PDE4 activator compound MR-L2 inhibits cyst formation.
Results
Small-Molecule Activators of Long-Form PDE4 Isoforms. During the
course of a chemistry program to develop PDE4 structure–
function probes and PDE4-selective inhibitors, we uncovered a
substituted triazole compound able to activate PDE4 long iso-
forms in a concentration-dependent manner. Taking this com-
pound as a starting point, we then embarked upon a campaign to
develop additional PDE4 activators as tool compounds with
which to further investigate their biological effects in vitro and
assess their therapeutic potential. This resulted in the generation
of a series of small-molecule PDE4 activators, exemplified by
MR-L2 in Fig. 1A (additional examples in SI Appendix, Fig. S1).
Four distinct genes (PDE4A, PDE4B, PDE4C, and PDE4D)
encode the PDE4 family of enzymes (8–10, 12, 29). As well as
being separated into four distinct gene families, catalytically
active PDE4 isoforms can be segregated into long, short, and
supershort isoform variants based upon the presence (or ab-
sence) of so-called UCR1 and UCR2 sequences (Fig. 2A) (9, 29).
MR-L2 (Fig. 1A), similarly activates representative PDE4 long-
isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5) from
each of the four PDE4 genes (Fig. 1B and SI Appendix, Fig.
S2A), albeit with a slightly enhanced magnitude of activation
observed for PDE4A4. Thus, for example, the commonly
expressed PDE4D5 isoform exhibited a ∼60% increase in ac-
tivity over basal levels at maximally effective concentrations of
MR-L2. This is of a similar magnitude to the level of endogenous
activation of PDE4D5 by PKA that elicits profound down-
regulation of cAMP (17, 29). As might be predicted, the stimu-
latory effects are specific to the PDE4 family, as demonstrated by
the failure of MR-L2 to enhance the activity of exemplars from
any of the other 10 families within the PDE superfamily (SI
Appendix, Fig. S2B).
The Activation of PDE4 Long Isoforms Mirrors Activation by PKA
Phosphorylation. Interestingly, the magnitude of PDE4 long-form
activation by MR-L2 (Fig. 1B) is comparable to the degree of ac-
tivation observed when PDE4 long isoforms are activated by the
PKA-mediated phosphorylation of a conserved serine located
within the UCR1 domain that is unique to long PDE4 isoforms and
absent from short/supershort isoforms (17, 19, 30, 31) (Fig. 2A and
SI Appendix, Fig. S2C). This suggested to us that the activator
Fig. 1. Exemplar long-form PDE4 activator com-
pound series. (A) An N-substituted-2-(3-aryl-1H-1,2,4-
triazol-1-yl)acetamide chemotype was identified with
long-form PDE4 activation properties, as exemplified
here with 2-(3-(4-chloro-3-fluorophenyl)-5-ethyl-
1H-1,2,4-triazol-1-yl)-N-(3,5-dichlorobenzyl)acetamide
(MR-L2). (B) MR-L2 activates representative long-form
PDE4 enzymes from each PDE4 family. Error bars
represent SD of at least four independent experi-
ments. (C) MR-L2 did not activate exemplar short
isoforms of PDE4A, B, and D families (PDE4C expresses
no short-form variants). (D) MR-L2 does not activate
an engineered construct expressing a truncated core
catalytic domain of PDE4D without UCR1, UCR2, and
C-terminal tail. Data from n = 4 separate experiments
shown as mean ± SD.
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compounds may phenocopy the PKA activation process. Indeed,
such levels of activation are physiologically relevant, providing a
major regulatory mechanism in terms of PKA-mediated feedback
allowing desensitization to cAMP signaling in PDE4 long-isoform–
expressing cells (17, 18). This feedback exerts a major impact on the
magnitude and duration of elevation of cAMP levels in cells sub-
sequent to the activation of adenylyl cyclase (16–18, 32, 33). In
contrast to its ability to activate PDE4 long isoforms, MR-L2 failed
to activate short PDE4 isoforms, which lack the regulatory
UCR1 domain and so are insensitive to activation by PKA (Fig.
1C). Moreover, the compound failed to activate engineered
PDE4 species that comprise solely a core, functional catalytic unit
deprived of both the regulatory UCR1 and UCR2 domains and the
C-terminal domain (Fig. 1D), again highlighting the requirement for
protein domains distal to the catalytic site in pharmacological ac-
tivation of PDE4 species. Furthermore, if the stimulatory effects of
the activator compound phenocopy the activation process engen-
dered by PKA phosphorylation of long PDE4 isoforms, then such
actions should not be additive. It is possible to mimic the PKA
phosphorylated state of PDE4 long isoforms by engineering a
Ser:Asp swap in the “Arg–Arg–Glu–Ser–Phe” PKA consensus motif
conserved in the UCR1 region of all PDE4 long isoforms (Fig. 2A)
(19, 30). The advantage of using such a mutant species is that it
ensures that the entire PDE4 long-form population under eval-
uation is in an activated state reflecting that achieved by PKA
phosphorylation. Indeed, we observed (Fig. 2B) that the S126D-
PDE4D5 mutant, which reflects a population of constitutively
activated enzyme (19, 30), exhibits a near-complete ablation to
pharmacological activation by challenge with MR-L2 (additional
in SI Appendix, Fig. S2D)
MAPKAPK2 (MK2) also phosphorylates PDE4 long forms in
UCR1, but at a different site (Ser133 of PDE4D5; Fig. 2A; ref.
Fig. 2. PDE4 activator treatment phenocopies PKA-
mediated activation of long PDE4 isoforms. (A) A
schematic diagram of PDE4 that details the muta-
tions used to investigate the action of MR-L2 on the
long PDE4 isoform, PDE4D5. (B) A S126D phospho-
mimetic substitution was used as a surrogate for PKA
phosphorylation. The S126D mimetic construct is not
activated by MR-L2, indicating that the activated
long-form PDE4 state engendered by the mutation is
insensitive to further pharmacological activation. (C)
S133D was engineered as a surrogate for MKII
phosphorylation of PDE4D5. Alone, the S133D sub-
stitution does not affect the activation of PDE4D5 by
MR-L2. However, when engineered in combination
with the PKA phosphomimetic, the S133D partially
restores the sensitivity to pharmacological activation
of the A S126D mutant enzyme. (D) The phosphor-
ylation of PDE4D5 by Erk was similarly simulated by
introducing a S651D mutation. MR-L2 activated this
construct, indicating that the activator can overcome
Erk phosphorylation-mediated inhibition of long-
form PDE4 activity. (E) A dimerization-deficient mu-
tant of PDE4D5 (DD1-R499D-PDE4D5) is unable to be
activated by MR-L2. (F) Eadie Hofstee analysis of
enzyme velocity showing the pharmacological acti-
vation of PDE4D5 with 3, 10, 30, and 100 μM MR-L2.
The activator compound increases PDE4D5 Vmax
without changing Km for cAMP. (G) Average Vmax
and Km values calculated from n = 4 independent
experiments ± SD.
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18) from that at which PKA acts. Instead of activation,
MK2 phosphorylation serves to attenuate the level of activation
elicited by PKA phosphorylation. We therefore investigated
whether the activity of MR-L2 could be influenced by MK2
phosphorylation using an engineered MK2 phosphomimetic
mutant (S133D-PDE4D5) that is known to mimic effectively the
MK2-phosphorylated protein state (18). We noted that the
S133D-PDE4D5 mutant, when examined in isolation, was acti-
vated by MR-L2 to a similar extent to wild-type PDE4D5 (Fig.
2C). Interestingly, while the PKA-phosphomimicking S126D-
PDE4D5 mutant was insensitive to pharmacological activation
by MR-L2 (Fig. 2B), the addition of a MK2 phosphomimetic
mutation alongside the phosphomimetic PKA mutation
(S126D:S133D-PDE4D5) acted to partially restore sensitivity
of the PKA phosphomimetic mutant of PDE4D5 to pharma-
cological activation by MR-L2 (Fig. 2C). This demonstrates
that additional posttranslational modification of long PDE4
isoforms can influence the pharmacological activation elicited
by MR-L2, including where prior PKA mediated phosphory-
lation and activation of long-form PDE4 enzymes is present.
In this instance, it seems likely that MR-L2 acts to overcome
the attenuating effect that MK2 phosphorylation exerts on
PKA activation of PDE4 long isoforms.
The growth-promoting kinase Erk is able to phosphorylate a
serine at the C-terminal end of the conserved PDE4 core catalytic
domain of isoforms of PDE4B, PDE4C, and PDE4D, but not
PDE4A forms (34). In the case of PDE4 long isoforms, phos-
phorylation by Erk leads to a reduction in PDE4 catalytic activity
that can be restored to basal levels by subsequent PKA-mediated
UCR1 phosphorylation, thereby providing a feedback regulatory
route in cells (32, 35). The Erk-inhibited state can be mimicked by
the cognate Ser:Asp mutation, as exemplified previously with the
Ser651Asp-PDE4D5 mutant (Fig. 2A) (32). In a manner that par-
allels the action of endogenous PKA phosphorylation (32), we show
here that MR-L2 challenge of Ser651Asp-PDE4D5 leads to a
comparable increase in activity to that seen when employing wild-
type PDE4D5 (Fig. 2D). Thus, treatment with the MR-L2 activator
compound phenocopies the action of PKA phosphorylation in
overcoming the ERK-mediated inhibition of PDE4 long-
isoform activity.
Activation by MR-L2 Requires the Dimeric Assembly of Long-Form
PDE4D5. PDE4 long isoforms form dimers (23, 36), and such
organization is essential for their autoinhibitory regulation by the
UCR modules and for their activation subsequent to PKA-
mediated phosphorylation (36). Dimerization involves two pivotal
binding interfaces. One of these is located in the PDE4 catalytic
unit, while the other involves the long-form UCR1 module forming
a four-helix bundle assembly with UCR2 in the dimer (23, 37–39).
Together, these interfaces confer an architecture that allows auto-
inhibitory cross-capping (40) of the catalytic pocket by UCR2 so as
to gate substrate entry. Simultaneous disruption of both di-
merization interfaces destroys the ability of full-length PDE4 long
isoforms to dimerize and results in the formation of long-form
monomers that, as with monomeric short forms, are catalytically
active (23). Long-form monomers can be engineered by mutations
at two discrete loci: namely triple alanine mutation of an Arg:
Asn:Asn motif (173-RNN-175 in PDE4D5) in the UCR1-located
dimerization interface combined with a single Arg-to-Asp charge
reversal mutation at the catalytic domain interface (R499 in
PDE4D5) (23). We have previously shown (23) that the monomeric
Arg173Ala:Asn174Ala:Asn175Ala:Arg499Asp-PDE4D5 mutant
(“DD1-R499D-PDE4D5”) lacks sensitivity to activation by PKA,
consistent with dismantling of the quaternary structure organization
that underpins regulatory cross-capping of the cAMP substrate
binding sites in the functional dimers. Here, we demonstrate a
parallel effect with the pharmacological activation of PDE4D5,
where the monomeric DD1-R499D-PDE4D5 mutant showed
complete loss of sensitivity to activation by MR-L2 (Fig. 2E).
This suggests that the mechanism of action of MR-L2, as with
PKA phosphorylation of long PDE4 isoforms, involves mod-
ulation of autoinhibitory UCR2 cross-capping within the PDE4
long-form dimeric assembly.
MR-L2 Elicits an Allosteric Activation of the PDE4D5 Long Isoform. As
PKA phosphorylation increases the Vmax for cAMP hydrolysis of
PDE4 long isoforms without affecting the Km for cAMP (19, 30,
31), we set out to determine the kinetics of MR-L2 action on
cAMP hydrolysis by PDE4D5. Indeed, MR-L2 acts as a re-
versible, noncompetitive activator of PDE4D5 (Fig. 2 F and G),
displaying an increase in the apparent Vmax for cAMP hydrolysis
without affecting the apparent Km for cAMP. Such kinetic data
are consistent with MR-L2 binding to an allosteric regulatory site
on PDE4 long isoforms to exert its stimulatory action.
The Pharmacological Activation of Long PDE4 Isoforms Lowers
Intracellular cAMP in Madin–Darby Canine Kidney Cells. ADPKD is
characterized by the formation and expansion of multiple cystic
structures arising from the tubular segments of the nephron. The
genetic abrogation of either polycystin-1 (PKD1) or polycystin-2
(PKD2) leads to diminished intracellular Ca2+ levels and,
thereby, the chronic activation of Ca2+-inhibited adenylyl cyclase-5/
6. This results in abnormally elevated cAMP levels that drive pro-
liferative signaling and enhanced fluid transport, resulting in the
formation, expansion, and swelling of multiple cystic structures
within the kidney (25, 26, 41). Madin–Darby canine kidney
(MDCK) cells maintain the normal integrity of epithelial cell po-
larity and adherens junctions, and can be triggered to form cysts
(cystogenesis) upon chronic stimulation of adenylyl cyclase, pro-
viding a cellular model for cAMP-dependent cyst formation in
ADPKD (24, 25, 42). MDCK cells express PDE4C and PDE4D
long-form variants as well as PDE4A and PDE4B short isoforms,
and their expression was unaffected by incubation with MR-L2 (Fig.
3A and SI Appendix, Fig. S2E). Upon challenging MDCK cells with
forskolin (3 μM; 15 min), a direct activator of adenylyl cyclase, we
found that cells that had been pretreated with MR-L2 exhibited
significantly suppressed cAMP elevation (Fig. 3B). These results
were further supported by cAMP-responsive fluorescence reso-
nance energy transfer (FRET) experiments, conducted in HEK293
cells, where MR-L2 suppressed the baseline-normalized cAMP
FRET response to forskolin (1 μM) (SI Appendix, Fig. S3A).
To confirm that the suppression of cAMP was due to the phar-
macologically enhanced activity of long-form PDE4 enzymes, we
then conducted a series of assays in the presence of the PDE4-
specific inhibitor, roflumilast (100 nM). We hypothesized that in-
hibition of PDE4 activity, through occupancy of the catalytic site by
the PDE4 inhibitor, would ablate the suppression of cAMP accu-
mulation by inactivating the catalytic activity of the PDE4 long-form
target of the allosteric activator. Indeed, we found that, in MDCK
cells, the inhibition of PDE4 activity, by a saturating concentration
of roflumilast (100 nM), ablated the suppressive effect of MR-L2
(3 μM), thereby confirming that the catalytic activity of PDE4 is
required for the action of MR-L2 (Fig. 3C).
Interestingly, cAMP is known to be excreted from the kidney
epithelia (see, e.g., ref. 43). For that reason, we investigated
whether the MR-L2–mediated reduction in intracellular cAMP
could be due to enhanced excretion from the MDCK cells. Thus,
we assessed the extracellular cAMP levels after forskolin (3 μM)
treatment of cells, with and without MR-L2 (3 μM) pre-
treatment. We found that, in parallel to the MR-L2–elicited
suppression of intracellular cAMP levels, the extracellular level
of cAMP was also significantly reduced by MR-L2 treatment
(Fig. 3D). This demonstrates that cAMP excretion is not en-
hanced by MR-L2 treatment and that reducing intracellular
cAMP levels, consequentially, leads to decreased cAMP export.
Omar et al. PNAS | July 2, 2019 | vol. 116 | no. 27 | 13323
B
IO
C
H
E
M
IS
T
R
Y
We confirmed that the activator compounds were not acting as
cytotoxic agents in these 2D culture assays using the xCELLi-
gence electrical-impedance–based assay system (Fig. 3E). The
expected exponential growth rate was observed for untreated
cells, and there was no effect of MR-L2 on cell number, dem-
onstrating a lack of overt cytotoxicity.
The Pharmacological Activation of Long PDE4 Isoforms Suppresses
MDCK Cyst Formation. Using the MDCK cell line as a model for
kidney cyst formation in 3D culture (24, 25, 42), we then in-
terrogated whether PDE4 activity can modulate cAMP-mediated
cyst expansion using the archetypal PDE4 inhibitor rolipram. We
found that the inhibition of PDE4 exacerbates agonist-driven
cyst formation in a concentration-dependent manner (Fig. 4A).
In this regard, it is possible that pan-PDE4 inhibitors used clin-
ically (7, 13, 14) may adversely exacerbate cyst formation in in-
dividuals either suffering from ADPKD or harboring mutations
that may lead to the clinical manifestations of ADPKD.
Having established that modulation of PDE4 activity regulates
the cAMP-mediated cystic response, we then tested whether am-
plifying PDE4-mediated cAMP degradation, using MR-L2, could
suppress the cystic phenotype. We evaluated this in cells chal-
lenged with a fixed concentration of PGE2 (300 nM), observing a
concentration-dependent suppression of cyst formation by MR-L2
(Fig. 4 B and C), with an EC50 of 1 μM. Interestingly, in the
cellular context, we found that the potency of MR-L2 was higher
than in the biochemical PDE4D5 enzyme activation assay. Such
enhanced cellular potency was seen in both the cAMP assay and
the cyst formation assay. This suggests that the functional long-
form PDE4 target in these cells has an enhanced sensitivity to
MR-L2 compared with the ectopically expressed PDE4 long iso-
forms in HEK293 cells, which may be due to cell type-conferred
differences in the conformation and/or posttranslational modifi-
cation status of the PDE4 long isoform. Indeed, there is a large
literature showing that PDE4 isoforms can show dramatically
different sensitivities to selective inhibitors dependent upon cel-
lular context (see, e.g., refs. 44–49). Such dramatic differences are
thought to be due to altered conformational changes in PDE4 that
may be triggered when PDE4 isoforms either interact with certain
partner proteins or are subject to specific types of posttransla-
tional modification. Examples of this are provided by, for example,
the PKA-mediated phosphorylation of PDE4D3 and the inter-
action of human PDE4A species with various SH3 domain-
containing proteins (9, 13, 22, 30, 50, 51).
To establish that the elevated catalytic activity PDE4 long
isoforms elicited by MR-L2 is required to suppress cyst forma-
tion, we investigated whether cotreatment with the potent
PDE4 inhibitor roflumilast (100 nM) was sufficient to ablate the
functionality of MR-L2 by inhibiting the catalytic activity of its
PDE4 target. We observed that treatment with roflumilast did,
indeed, interdict the suppression of cystogenesis elicited by the
pharmacological PDE4 activator MR-L2 (3 μM, Fig. 4D).
ATP levels have previously been connected with cyst forma-
tion and expansion in the MDCK cell model (52). We therefore
set out to determine whether downstream modulation of ATP
signaling, in response to long-form PDE4 activation, may con-
tribute to the suppression of cyst formation. We assessed this by
measuring the abundance of DNA-normalized ATP levels in
whole-well cystic cultures, where we observed a slight reduction
(15.6 ± 30% SD) in the ATP/DNA ratio when cells were grown
in the presence of MR-L2 (3 μM; Fig. 4E).
The differential expression and activity of adenylyl cyclase
isoforms has been shown to occur in ADPKD (53, 54), and the
AC3, AC5, and AC6 isoforms are expressed in MDCK cells (53,
54). To investigate whether the suppression of cAMP-driven
cystogenesis was independent of the mode of activation of ade-
nylyl cyclase, we evaluated a single, nonmaximally effective,
concentration of MR-L2 (3 μM) against either (i) incremental
increases in forskolin concentration (Fig. 5A), to drive cysto-
genesis by direct activation of adenylyl cyclase, or (ii) PGE2
stimulation (Fig. 5B), to evaluate cystogenesis driven by the
Gs-coupled receptor-promoted activation of adenylyl cyclase.
The activator, MR-L2, clearly suppressed the maximal cyst
response elicited by both such direct and indirect activation of
adenylyl cyclase.
Fig. 3. MR-L2 reduces intracellular cAMP in MDCK cells without affecting
PDE4 expression or cell viability. (A) MDCK cells were grown in 2D culture
and treated with increasing concentrations of MR-L2. Western blot analysis
of protein extracts shows the expression of short-form PDE4A and PDE4B and
PDE4D, as well as long forms of PDE4C and PDE4D. Based upon their observed
gel migration and predicted molecular weights, these bands are likely to rep-
resent PDE4A1, PDE4B2, PDE4C1/3, PDE4D1/2, PDE4D5/7, and PDE4D3/8/9 (in
some cases, multiple isoform variants comigrate due to similar molecular
weights). The expression of these isoform variants was not affected by 1-h in-
cubation withMR-L2. β-Actin was used as a protein loading control. Quantitation
of multiple Western blot analysis is presented in SI Appendix, Fig. S2E. (B) A 1-h
pretreatment with MR-L2 suppresses cAMP accumulation in response to acute
treatment with 3 μM forskolin (15 min). Mean of n = 7 independent experiments
(±SD). Data points represent independent experimental results. (C) The sup-
pressive effects of 1-h pretreatment with 3 μM MR-L2 on forskolin (3 μM,
15 min)-stimulated cAMP accumulation was ablated by cotreatment with the
PDE4 inhibitor roflumilast (100 nM). Results show the mean of three in-
dependent experiments, and error bars represent SD. (D) Extracellular cAMP was
assessed in response to MR-L2 (3 μM) incubation for 1 h before forskolin (3 μM,
15 min) challenge. Extracellular cAMP accumulation was reduced in the MR-
L2 samples, indicating that the intracellular reduction in global cAMP was not
due to enhanced excretion from the cell. Data from three independent experi-
ments are shown. (E) MR-L2 treatment exhibited no deleterious effects on the
proliferation of MDCK cells in 2D culture using the xCELLigence impedance-
based assay system. MR-L2 was added to the culture 24 h after inception of
the assay.
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Activation of PDE4 Long Isoforms Suppresses cAMP-Dependent Cystic
Fibrosis Transmembrane Receptor Activation. The cystic fibrosis
transmembrane receptor (CFTR) chloride channel is expressed
in many tissues including kidney epithelia (55). In response to
elevated cAMP, PKA phosphorylates the CFTR at multiple in-
tracellular residues, resulting in channel activation and chloride
transport (55). PDE4D long isoforms localize with the CFTR
signaling complex and regulate channel activity by lowering local
cAMP levels and, thereby, associated PKA activity (56, 57). In
ADPKD, activated CFTR facilitates fluid transport into the cystic
lumen (55).
MDCK cells retain expression of CFTR, and the role of this ion
channel in cyst expansion in this model is well recognized (24, 25,
42, 58, 59). We investigated whether increased cAMP hydrolysis,
induced by MR-L2, could suppress CFTR activation in MDCK cells
using a membrane depolarization (60). We found that PGE2 treat-
ment depolarizedMDCK cell membrane potential in a concentration-
dependent manner (Fig. 5C) and this was reversed by the addition
of a selective CFTR inhibitor (CFTRINH172, 100 μM) (SI Appen-
dix, Fig. S3B). Interestingly, PGE2-elicited CFTR activity was
clearly suppressed in a concentration-dependent manner upon
MR-L2 pretreatment (Fig. 5D). Interestingly, the dose depen-
dency of MR-L2, for both inhibition of MDCK cystogenesis and
CFTR depolarization, was near identical when employing PGE
stimulation, at either 300 or 100 nM (Fig. 5 E and F, respectively).
PDE4 Activation Suppresses Cyst Formation in Human Cell Models of
ADPKD. We further studied the action of MR-L2 in human
models of ADPKD by first profiling the PDE4 isoform compo-
sition in four normal (CL5, CL8, CL11, and RFH), and four
ADPKD patient-derived cell lines (SKI-001, SKI-002, OX938,
and OX161) (42, 61) (SI Appendix, Fig. S3C). We found that
long PDE4B1, PDE4B3, PDE4C3, PDE4D5, PDE4D7, and
PDE4D9 isoform as well as short PDE4B2 and PDE4D1/
PDE4D2 isoform transcripts were expressed in these cells. Of
these transcripts, we found that those for long PDE4D5 and for
short PDE4D1/2 were up-regulated in ADPKD cells (SI Ap-
pendix, Fig. S3C). This is consistent with the elevated levels of
cAMP driving increased gene expression by virtue of functional
CRE motifs known to be located within the promoter elements
of their genes (62, 63). Interestingly, we observed the expression
of long PDE4C species in the MDCK cell model (Fig. 3A) and
detected an elevated mRNA expression in two of the human
ADPKD mRNA samples. PDE4C exhibits a very restricted ex-
pression pattern compared with other PDE4 subfamilies, but it
has been connected with the regulation of a PC-2/AKAP150/
PKA localized signalosome in the primary cilia and, further-
more, the regulation of PDE4C isoforms by HNF-1 has been
linked to ADPKD (64).
We selected one of these immortalized ADPKD kidney cell
lines to examine the action of MR-L2 in a cellular context. The
immortalized OX161 line was first isolated from a patient with
ADPKD who expressed a truncated, nonfunctional form of
polycystin-1 (PC1) (42). As with MDCK cells, OX161 cells are
responsive to agonists of cAMP signaling, such as forskolin and
PGE2, which drive the formation of small cystic structures when
cells are grown in a 3D matrix (42). As with the MDCK cell
model, we found that, in OX161 cells, cystogenesis is enhanced
upon challenge with the PDE4 inhibitor, rolipram (Fig. 6A),
highlighting the fact that PDE4 activity serves to regulate cystic
Fig. 4. MDCK cyst formation is regulated by PDE4
activity and is suppressed by pharmacological acti-
vation of PDE4 long isoforms. (A) MDCK cells were
grown in a 3D collagen matrix and treated with in-
creasing concentrations of the PDE4-selective in-
hibitor, rolipram. Rolipram exacerbates the PGE2-
induced formation of large cystic structures, dem-
onstrating that PDE4 enzymes are localized within
compartments that control cyst expansion. (B) PGE2-
induced MDCK cell cyst formation was suppressed by
MR-L2 (EC50, 1.2 μM). Data are displayed as a per-
centage of PGE2 stimulation alone, and error bars
represent the SEM of all cysts measured in each
condition. (C) Representative images of MDCK cysts
treated with increasing concentrations of MR-L2.
The images illustrate a concentration-dependent
suppression of cyst size. (D) Cotreatment of PGE2
(300 nM)-stimulated MDCK cystic cultures with
roflumilast (100 nM) and/or MR-L2 (3 μM) shows that
inhibition of PDE4 catalytic activity ablates the sup-
pressive effects of MR-L2 on cyst growth. Error bars
represent the SEM. Representative images of MR-L2,
and roflumilast/MR-L2–treated cultures are shown.
(E) DNA normalized ATP concentrations within the
cystic cultures were used as a measurement ATP in
the cystic cultures. The balance of ATP signaling in
the cystic cultures was not perturbed by MR-L2
treatment.
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potential of human ADPKD cells. Similar to what we observed
with MDCK cells, we found that MR-L2 attenuated the PGE2-
stimulated cystogenesis of OX161 cells (Fig. 6B).
PDE4 Activation Suppresses Cyst Formation in Primary Cultures of
ADPKD Patient-Derived Kidney Epithelial Cells. We then went on
to assess the functionality of MR-L2 in primary human cell cul-
tures that were collected from the cysts of an ADPKD patient’s
kidney. Such cells form fluid-filled cysts in 3D culture and are
responsive to stimuli that increase cAMP, such as forskolin (SI
Appendix, Fig. S4A) and PGE2 (SI Appendix, Fig. S4B). In-
terestingly, while immortalized culture models such as OX161
cells fail to respond to vasopressin, an important accentuator of
cyst formation, these primary cells were found to be vasopressin-
sensitive (SI Appendix, Fig. S4C), thus mirroring the pathological
situation in vivo. It must be noted, however, that at the concen-
trations of AVP tested, this Gs-coupled receptor agonist elicited a
lower level of stimulation than did the Gs-coupled receptor ago-
nist PGE2. This may reflect cAMP compartmentalization such
that these receptors activate distinct pools of adenylyl cyclases,
showing not only different degrees of activation but also different
spatial localization within the plasma membrane conferring dis-
tinct cellular functionalities and potential for being differentially
regulated by distinct long-form PDE4 populations. Consistent with
their origins in diseased kidney tissue, these primary cell cultures
spontaneously form large cystic structures in vitro (Fig. 6C).
Furthermore, MR-L2 clearly suppressed the number of cysts
formed in 3D culture in both unstimulated (Fig. 6C) and
vasopressin-treated (10 nM) cell cultures (Fig. 6D) without ad-
versely affecting cell viability (Fig. 6 E–G).
Discussion
PDE4 family isoforms are ubiquitously expressed and play a
fundamental role in determining the spatial compartmentaliza-
tion of cAMP signaling in cells. They also act as nodes for
conferring cross talk via inputs from various other signaling
pathways through multisite phosphorylation (8, 10, 12, 13, 29).
Furthermore, long PDE4 isoforms play a key role in determining
cellular desensitization to cAMP signaling through a feedback
loop involving their PKA-mediated phosphorylation and activation
(17, 18, 65). This process is restricted to long PDE4 isoforms, as
PKA phosphorylates a serine residue located within UCR1 (a
regulatory module conserved across long isoforms from all
PDE4 subfamilies) but that is absent from PDE4 short and super-
short forms and is not found in any other PDE family (19, 30, 31).
The adjacent UCR2 region, although found in all PDE4 isoforms
(whether long or short), exerts an autoinhibitory action that is
specific to the long forms and serves to diminish, but does not fully
abolish, their catalytic activity (37). The mechanistic basis for this
arises from the interaction of UCR2 with UCR1. Thus, together,
UCR2 and UCR1 interact to form a combined regulatory module
(66) that docks over the catalytic pocket (38). This UCR1/2 module
imposes a constraint on long-form PDE4 catalytic activity that is
ablated by PKA phosphorylation of UCR1, leading to an increase in
activity of, typically, some 40–80% (19, 22, 29, 37, 38). Given the
high catalytic turnover of PDE4, this degree of activation has the
ability to generate a profound decrease in cAMP levels in cells,
thereby regulating cAMP-responsive processes (17–19, 65).
Here, we describe the discovery of a long-form PDE4-
activating ligand, namely, the N-substituted-2-(3-aryl-1H-1,2,4-
triazol-1-yl)acetamide chemotype of MR-L2 (Fig. 1A). It acts to
Fig. 5. MR-L2 treatment-mediated MDCK cyst sup-
pression is independent of agonist drive and sup-
presses PGE2-mediated CFTR activation and membrane
depolarization. (A) Forskolin treatment drives cyst for-
mation and expansion in a concentration-dependent
manner. Activator compound MR-L2 (3 μM) sup-
pressed forskolin-induced cyst formation. Data are dis-
played as mean ± SEM of all cysts measured in each
experimental condition. (B) PGE2-stimulated MDCK cyst
formation was also suppressed by PDE4 long-form ac-
tivation with 3 μMMR-L2. Data are displayed as mean±
SEM of all cysts measured in each experimental condi-
tion. (C) MDCK cells exhibit a concentration-dependent
membrane depolarization in response to PGE2-
mediated CFTR activation using a fluorescent dye-
based assay for membrane potential. Individual
fluorescence traces over time are shown for each
PGE2 concentration. T1 highlights the time point at
which PGE2 was added. (D) Cells were preincubated
(40 min) with concentrations of the PDE4 long-form
activator compound MR-L2, and then challenged
with 100 nM PGE2. Increasing concentrations of MR-
L2 suppress the PGE2-stimulated increase in fluores-
cence, indicating that activation of PDE4 is sufficient
to dampen the cAMP-driven activation of the CFTR.
(E and F) Cyst assays were conducted in parallel with
CFTR assessment. When MDCK cells are stimulated to
form cysts with either 300 nM PGE2 (E) or 100 nM
PGE2 (F), the resulting concentration-dependent
suppression of cystic expansion by MR-L2 (black
bars, shown as percentage of PGE2 alone; error bars
are SEM of all cysts measured in each treatment)
closely follows the down-regulation of CFTR-
mediated membrane depolarization (gray bars, fold
change in fluorescence).
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phenocopy the stimulatory effect exerted by PKA phosphoryla-
tion on dimeric PDE4 long isoforms (19, 31, 35, 37). Thus, we
have shown that the stimulatory effect of MR-L2 (i) is restricted
to PDE4 family enzymes and specific to long-form variants; (ii)
that it is not additive with the stimulatory effect of PKA on long
isoforms; (iii) that it requires the dimeric state that is adopted by
long, but not short, PDE4 isoforms; (iv) that it is operative on
PDE4 long isoforms showing attenuated activity due to phos-
phorylation by Erk MAP kinase; and (v) that it elicits compa-
rable levels of activation to those caused by PKA-mediated
phosphorylation of PDE4 long isoforms.
The action of MR-L2 is reversible and exhibits kinetics of non-
competitive activation. These data are consistent with the com-
pounds binding to an allosteric site on the enzyme. We propose
that, as has been suggested for PKA phosphorylation-mediated
activation, this drives an equilibrium shift away from a UCR1/
UCR2-capped autoinhibited conformational state toward dis-
inhibited conformational state(s) (29, 37, 38). It is known that
UCR1 engages with UCR2 directly to form a tandem regulatory
module (66). Insight into a mechanism whereby the UCR1/
UCR2 module might regulate catalytic activity has been gauged
from crystal structures showing that a helix within UCR2 can fold
across the entrance to the catalytic pocket to gate substrate entry
(67). Although complete structural characterization of full-length
PDE4 species remains elusive, further advances with crystallo-
graphic studies (40) have now unambiguously confirmed hypotheses
(40, 68) that UCR2 gating of the catalytic pocket involves cross-
capping within the dimeric long-form PDE4 structures. Thus, reg-
ulatory control of long-form PDE4 activity requires the enzyme to
be in a dimeric configuration with alterations in activity likely me-
diated by modulation of the equilibrium position between the
UCR2-capped and -uncapped states, thereby exerting Vmax kinetic
control over cAMP hydrolysis. Presumably, such a transition leading
to uncapping and increased catalytic activity can be triggered either
natively, when PKA phosphorylates UCR1, or pharmacologically,
when a small-molecule activator binds to its allosteric site.
As with PKA phosphorylation (17–19, 30), we show that the
prototypical allosteric activator, MR-L2, can decrease in-
tracellular cAMP levels in cells where long PDE4 isoforms are
expressed. Moreover, it is expected that the observed reduction
in global cAMP concentration will not be homogenously dis-
tributed throughout the cell, and that effects may be more pro-
nounced at key nanodomain signaling complexes. At such sites in
intact cells, the protein complexation and or posttranslational
modification status of target PDE4 species may give rise to al-
tered sensitivity to activator compounds relative to that seen in
our biochemical enzyme assay based on cell lysates. Such com-
pounds might have therapeutic potential in diseases where
chronic cAMP elevation provides the underpinning molecular
pathology. One such disease is ADPKD (21, 26, 41, 69). This is a
genetically defined disease that is underpinned by mutations in
PKD1 or PKD2, leading to loss or diminution of their function.
The consequences of this are lowered intracellular Ca2+ levels
that lead to disinhibition of adenylyl cyclases-5/6 and thence to
elevation of cAMP. Such chronically elevated cAMP levels drive
the formation and swelling of kidney cysts that, eventually, lead
to kidney failure. The variety of PDE4 long isoforms that kidney
cells express (70, 71) (Fig. 3A and SI Appendix, Fig. S3C) provide
targets for activator compounds such as MR-L2, suggesting a
potential therapeutic strategy. Indeed, we show here that not
only does MR-L2 decrease intracellular cAMP but that it also
attenuates CFTR activity, which is stimulated by cAMP-driven
activation of PKA, and cyst formation in the model MDCK cell
system. MR-L2 was also successful in suppressing cyst expansion
in an immortalized kidney cell line, OX161, derived from an
ADPKD patient, and we further show that the compound sup-
presses the formation of cysts in 3D cultures of primary human
kidney epithelial cells isolated from an ADPKD patient.
Fig. 6. MR-L2 inhibits cyst formation in human models of ADPKD. (A)
Treatment with the PDE4-selective inhibitor, rolipram, exacerbates the ex-
pansion of cysts formed by the OX161 cell line when grown in 3D culture.
Data are expressed as a percentage of vehicle [0.1% (vol/vol) DMSO]
control treatment and displayed as mean ± SEM of all cysts measured in
each condition. (B) MR-L2 suppresses the formation of PGE2-stimulated
OX161 cell cysts in a concentration-dependent manner. Mean cyst size is
shown as a percentage of the PGE2-alone treatment group, where MR-
L2 reduces mean cyst size to below unstimulated [0.1% (vol/vol) DMSO]
levels. (C ) Primary human cells from a patient with ADPKD were cultured
from single kidney cysts. MR-L2 suppresses the spontaneous cyst for-
mation of diseased primary human kidney epithelial cells. Cyst number
decreases in response to MR-L2 treatment. Error bars represent the SD of
four treatments. (D) MR-L2 suppresses the vasopressin-exacerbated,
ADPKD-driven, cyst formation of diseased primary human kidney epi-
thelial cells. Cyst number decreases in response to MR-L2 treatment.
Error bars represent the SD of four treatments. (E and F ) Primary human
ADPKD cell viability was not adversely affected by MR-L2 treatment, as
assessed using a luminescence-based detection of ATP as a function of
living cells. Data are displayed in relative luminescence units, with error
bars representing the SD of four treatments. (G) Composite confocal
microscopy of primary human cystic cultures under treatment with
10 nM vasopressin and concentrations of MR-L2. Cystic structures are
seen as spherical, lumen-forming, cellular outgrowths. Epithelial tubules
and supporting cellular matrices are also present within the cultures but
are not overtly affected by the presence of MR-L2 (additional imaging
available in SI Appendix, Fig. S4).
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In summary, MR-L2 pharmacologically activates dimeric
PDE4 long-form variants through a mechanism that phenocopies
both the magnitude and mechanism of PKA-mediated PDE4
long-isoform activation. This provides a route to evaluate the
consequences of specifically activating this group of PDE4 iso-
forms. Moreover, the discovery and initial characterization
of this drug-like PDE4 activator, together with the demon-
stration that it can inhibit the in vitro formation of kidney
cysts that characterize ADPKD, suggests that direct phar-
macological activation of PDE4 long forms may have thera-
peutic utility in diseases driven by chronically up-regulated
cAMP levels.
Materials and Methods
Chemicals and Reagents. Unless otherwise specified, reagents were sourced
from Sigma-Aldrich. MR-L2 was synthesized as described in patent
WO2016151300.
Cell Culture. HEK293 and MDCK (ATCC) cells were cultured in DMEM (Lonza)
supplemented with 10% (vol/vol) FBS (Invitrogen). Human primary epithelial
cells were sourced from DiscoveryBioMed and cultured in proprietary
media supplied by DBM. Transfection into mammalian cells was con-
ducted using the Lipofectamine 3000 reagent (Invitrogen) as per the
manufacturer’s instruction.
Molecular Biology. pcDNA3.1 (Invitrogen) was used as the standard vector for
mammalian expression, and all site-directed mutagenesis was conducted
using the QuikChange mutagenesis kit (Agilent Technologies).
cAMP Phosphodiesterase Assay. Cellswere collected in KHEMbuffer [50mMKCl,
10 mM EGTA, 50 mM Hepes (pH 7.2), 1.92 mM MgCl2, pH 7.4 with KOH] and
lysed by mechanical disruption. Lysate was precleared by centrifugation at
2,000 × g for 10 min before centrifugation at 100,000 × g for 30 min. The
protein concentration of the supernatant was determined by BCA assay (Sigma).
The cAMP PDE assays were then conducted as previously described, using pro-
tein concentrations (typically 200 ng to 1 μg per reaction) and incubation times
(10 min) that yielded linear rates of reaction as described before by us (72).
Western Blot. Cells were lysed for 20 min in a whole-cell lysis buffer [1% (vol/vol)
Triton X-100, 25mMHepes, 2.5mMEDTA, 150mMNaCl, 50mMNaF, and 30mM
NaPPi] containing a protease inhibitor mixture (Roche). Insoluble material was
removed by centrifuge at 14,000 × g. Protein concentration was measured by
standard BCA assay (Sigma) before the addition of SDS sample buffer (Invi-
trogen). The antisera raised against PDE4 have previously been described (19, 73).
cAMP ELISA. Assays were conducted using a cAMP ELISA kit (Enzo) following
the manufacturer’s instructions and using pre-prepared reagents supplied by
the manufacturer.
MDCK Cyst Assay. Collagen type I from rat tail (Invitrogen) was used to form
the 3D matrix for culture of MDCK cystic organoids. The assays were con-
ducted in 24- or 96-well plate format with a final concentration of 1 mg/mL
collagen matrix. Images were captured using a Motic phase contrast mi-
croscope set at 4× magnification. Cystic diameter was recorded, from which
cyst volume (V) was calculated using the formula V = 4/3 π r3, where r is the
radius of the cyst. Typically, between 100 and 300 cysts were measured in
each treatment condition, expressed as mean cystic volume ± SEM. DNA
normalized ATP levels were measured upon completed of cyst assays where
DNA was first labeled using 20 μM Hoechst for 1 h at 37 °C and quantified by
fluorescence measurement at 361–486 nm. ATP levels were then assessed
using CellTiter-Glo 3D reagent (Promega).
xCELLigence Assays. Assays were conducted as previously described (74).
MDCK cells were plated at a density of 5,000 cells per well and allowed to
adhere for 24 h before treatment.
OX161 Cyst Assay. OX161 cells were cultured, and assays were conducted as
previously described (42, 61).
Primary Human Kidney Cell Cyst Assay. Single-cyst–derived or tissue-derived
primary cultures were derived from kidney tissue specimens from de-identified
human ADPKD patients under Western Institutional Review Board (WIRB) ap-
proval. Informed consent was obtained by third-party vendor interchanges
(National Disease Research Interchange and American Association of Tissue
Banks) that procure remnant human tissue for biomedical research. Primary
human ADPKD cells were grown in biogels containing DiscoveryBioMed Renal-
Cyte media. Manual imaging and cyst counting was conducted in 96-well plates,
and automated imaging of the entire well of 384-well plates was conducted.
CFTR Assay. MDCK cells were seeded in 96-well clear-bottom assay plates 4 d
before inception of the assay. Assays were conducted in low Cl− buffer
[140 mM Na gluconate, 5 mM K gluconate, 10 mM glucose, 10 mM Hepes
(free acid), 1 mM CaCl2, 1 mMMgCl2, pH 7.4 with NaOH] supplemented with
FLIPR Membrane Potential Assay Kit Blue (Molecular Devices; R8042) and
Amiloride (10 μM) (75). Assays were conducted using the Flex Station 3
(Molecular Devices), where real-time measurements of fluorescence were
recorded at excitation 530 nm and emission 565 nm.
Statistical Analysis. Pairwise comparison of data was conducted by t test, or
Mann–Whitney test. One-way ANOVA with Dunnett’s multiple-comparison
test was conducted where multiple comparisons within the data were made.
Statistical significance is annotated as follows: ***P ≤ 0.001, **P ≤ 0.01, and
*P ≤ 0.05.
ACKNOWLEDGMENTS. A.C.M.O. and M.L. acknowledge research support
from Kidney Research United Kingdom (Grant RP40/2014). E.K. acknowl-
edges research support from Bundesministerium für Bildung und For-
schung (16GW0179K), Deutsche Forschungsgemeinschaft (KL1415/7-1
and 394046635–SFB 1365), and the German–Israeli Foundation (I-1452-
203/13-2018).
1. K. Taskén, E. M. Aandahl, Localized effects of cAMP mediated by distinct routes of
protein kinase A. Physiol. Rev. 84, 137–167 (2004).
2. E. Parnell, T. M. Palmer, S. J. Yarwood, The future of EPAC-targeted therapies: Ago-
nism versus antagonism. Trends Pharmacol. Sci. 36, 203–214 (2015).
3. M. Schmidt, F. J. Dekker, H. Maarsingh, Exchange protein directly activated by cAMP
(epac): A multidomain cAMP mediator in the regulation of diverse biological func-
tions. Pharmacol. Rev. 65, 670–709 (2013).
4. R. F. Schindler, T. Brand, The Popeye domain containing protein family—a novel class
of cAMP effectors with important functions in multiple tissues. Prog. Biophys. Mol.
Biol. 120, 28–36 (2016).
5. D. H. Maurice et al., Advances in targeting cyclic nucleotide phosphodiesterases. Nat.
Rev. Drug Discov. 13, 290–314 (2014).
6. T. Keravis, C. Lugnier, Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.
Curr. Pharm. Des. 16, 1114–1125 (2010).
7. S. H. Francis, M. A. Blount, J. D. Corbin, Mammalian cyclic nucleotide phosphodies-
terases: Molecular mechanisms and physiological functions. Physiol. Rev. 91, 651–690
(2011).
8. M. D. Houslay, Underpinning compartmentalised cAMP signalling through targeted
cAMP breakdown. Trends Biochem. Sci. 35, 91–100 (2010).
9. M. D. Houslay, G. S. Baillie, D. H. Maurice, cAMP-Specific phosphodiesterase-4 en-
zymes in the cardiovascular system: A molecular toolbox for generating compart-
mentalized cAMP signaling. Circ. Res. 100, 950–966 (2007).
10. M. Conti et al., Cyclic AMP-specific PDE4 phosphodiesterases as critical components of
cyclic AMP signaling. J. Biol. Chem. 278, 5493–5496 (2003).
11. A. Lerner, P. M. Epstein, Cyclic nucleotide phosphodiesterases as targets for treatment
of haematological malignancies. Biochem. J. 393, 21–41 (2006).
12. M. D. Houslay, PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol.
Biol. 69, 249–315 (2001).
13. M. D. Houslay, P. Schafer, K. Y. Zhang, Keynote review: Phosphodiesterase-4 as a
therapeutic target. Drug Discov. Today 10, 1503–1519 (2005).
14. C. P. Page, D. Spina, Phosphodiesterase inhibitors in the treatment of inflammatory
diseases. Handb. Exp. Pharmacol., 391–414 (2011).
15. S. L. Jin, S. L. Ding, S. C. Lin, Phosphodiesterase 4 and its inhibitors in inflammatory
diseases. Chang Gung Med. J. 35, 197–210 (2012).
16. D. Mika, M. Conti, PDE4D phosphorylation: A coincidence detector integrating mul-
tiple signaling pathways. Cell. Signal. 28, 719–724 (2016).
17. N. Oki, S. I. Takahashi, H. Hidaka, M. Conti, Short term feedback regulation of cAMP
in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J. Biol. Chem.
275, 10831–10837 (2000).
18. K. F. MacKenzie et al., Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-
4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phos-
phorylation. Biochem. J. 435, 755–769 (2011).
19. S. J. MacKenzie et al., Long PDE4 cAMP specific phosphodiesterases are activated by
protein kinase A-mediated phosphorylation of a single serine residue in upstream
conserved region 1 (UCR1). Br. J. Pharmacol. 136, 421–433 (2002).
20. G. Némoz, C. Sette, M. Conti, Selective activation of rolipram-sensitive, cAMP-specific
phosphodiesterase isoforms by phosphatidic acid. Mol. Pharmacol. 51, 242–249
(1997).
13328 | www.pnas.org/cgi/doi/10.1073/pnas.1822113116 Omar et al.
21. L. Wang et al., UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms
and attenuates cardiomyocyte hypertrophy. Cell. Signal. 27, 908–922 (2015).
22. W. Richter, M. Conti, The oligomerization state determines regulatory properties and
inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J. Biol. Chem. 279,
30338–30348 (2004).
23. G. B. Bolger et al., Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells
requires interfaces located in both the UCR1 and catalytic unit domains. Cell. Signal.
27, 756–769 (2015).
24. R. Mangoo-Karim, M. Uchic, C. Lechene, J. J. Grantham, Renal epithelial cyst forma-
tion and enlargement in vitro: Dependence on cAMP. Proc. Natl. Acad. Sci. U.S.A. 86,
6007–6011 (1989).
25. D. P. Wallace, Cyclic AMP-mediated cyst expansion. Biochim. Biophys. Acta 1812,
1291–1300 (2011).
26. V. E. Torres, P. C. Harris, Strategies targeting cAMP signaling in the treatment of
polycystic kidney disease. J. Am. Soc. Nephrol. 25, 18–32 (2014).
27. A. C. M. Ong, O. Devuyst, B. Knebelmann, G. Walz; ERA-EDTA Working Group for
Inherited Kidney Diseases, Autosomal dominant polycystic kidney disease: The
changing face of clinical management. Lancet 385, 1993–2002 (2015).
28. A. C. M. Ong, P. C. Harris, A polycystin-centric view of cyst formation and disease: The
polycystins revisited. Kidney Int. 88, 699–710 (2015).
29. M. D. Houslay, D. R. Adams, PDE4 cAMP phosphodiesterases: Modular enzymes that
orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem.
J. 370, 1–18 (2003).
30. R. Hoffmann, I. R. Wilkinson, J. F. McCallum, P. Engels, M. D. Houslay, cAMP-specific
phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in roli-
pram inhibition triggered by protein kinase A phosphorylation of Ser-54: Generation
of a molecular model. Biochem. J. 333, 139–149 (1998).
31. C. Sette, M. Conti, Phosphorylation and activation of a cAMP-specific phosphodies-
terase by the cAMP-dependent protein kinase. Involvement of serine 54 in the en-
zyme activation. J. Biol. Chem. 271, 16526–16534 (1996).
32. G. Baillie, S. J. MacKenzie, M. D. Houslay, Phorbol 12-myristate 13-acetate triggers the
protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP
phosphodiesterase in human aortic smooth muscle cells through a route involving
extracellular signal regulated kinase (ERK). Mol. Pharmacol. 60, 1100–1111 (2001).
33. F. Naro et al., Involvement of type 4 cAMP-phosphodiesterase in the myogenic dif-
ferentiation of L6 cells. Mol. Biol. Cell 10, 4355–4367 (1999).
34. G. S. Baillie, S. J. MacKenzie, I. McPhee, M. D. Houslay, Sub-family selective actions in
the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of
PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 131, 811–819 (2000).
35. R. Hoffmann, G. S. Baillie, S. J. MacKenzie, S. J. Yarwood, M. D. Houslay, The MAP
kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phos-
phorylating it at Ser579. EMBO J. 18, 893–903 (1999).
36. M. Xie et al., The upstream conserved regions (UCRs) mediate homo- and hetero-
oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s). Biochem. J.
459, 539–550 (2014).
37. W. Richter, M. Conti, Dimerization of the type 4 cAMP-specific phosphodiesterases is
mediated by the upstream conserved regions (UCRs). J. Biol. Chem. 277, 40212–40221
(2002).
38. P. Cedervall, A. Aulabaugh, K. F. Geoghegan, T. J. McLellan, J. Pandit, Engineered
stabilization and structural analysis of the autoinhibited conformation of PDE4. Proc.
Natl. Acad. Sci. U.S.A. 112, E1414–E1422 (2015).
39. M. E. Lee, J. Markowitz, J. O. Lee, H. Lee, Crystal structure of phosphodiesterase 4D
and inhibitor complex(1). FEBS Lett. 530, 53–58 (2002).
40. M. D. Houslay, D. R. Adams, Putting the lid on phosphodiesterase 4. Nat. Biotechnol.
28, 38–40 (2010).
41. F. T. Chebib, C. R. Sussman, X. Wang, P. C. Harris, V. E. Torres, Vasopressin and dis-
ruption of calcium signalling in polycystic kidney disease. Nat. Rev. Nephrol. 11, 451–
464 (2015).
42. E. Parker et al., Hyperproliferation of PKD1 cystic cells is induced by insulin-like
growth factor-1 activation of the Ras/Raf signalling system. Kidney Int. 72, 157–165
(2007).
43. R. A. M. H. van Aubel, P. H. E. Smeets, J. G. P. Peters, R. J. M. Bindels, F. G. M. Russel,
The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human
kidney proximal tubules: Putative efflux pump for urinary cAMP and cGMP. J. Am.
Soc. Nephrol. 13, 595–603 (2002).
44. J. E. Souness, S. Rao, Proposal for pharmacologically distinct conformers of PDE4 cyclic
AMP phosphodiesterases. Cell. Signal. 9, 227–236 (1997).
45. S. D. Boomkamp, M. A. McGrath, M. D. Houslay, S. C. Barnett, Epac and the high
affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and
myelination using an in vitro spinal cord injury model. Br. J. Pharmacol. 171, 2385–
2398 (2014).
46. M. S. Barnette et al., Inhibitors of phosphodiesterase IV (PDE IV) increase acid secre-
tion in rabbit isolated gastric glands: correlation between function and interaction
with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 273, 1396–1402
(1995).
47. M. S. Barnette et al., SB 207499 (Ariflo), a potent and selective second-generation
phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J. Pharmacol. Exp.
Ther. 284, 420–426 (1998).
48. H. -T. Zhang et al., Antidepressant-like effects of PDE4 inhibitors mediated by the
high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme
(PDE4) in rats. Psychopharmacol. (Berl). 186, 209–217 (2006).
49. Y. Zhao, H.-T. Zhang, J. M. O’Donnell, Inhibitor binding to type 4 phosphodiesterase
(PDE4) assessed using [3H]Piclamilast and [3H]. Rolipram. 305, 565–572 (2003).
50. I. McPhee et al., Association with the SRC family tyrosyl kinase LYN triggers a con-
formational change in the catalytic region of human cAMP-specific phosphodiester-
ase HSPDE4A4B. Consequences for rolipram inhibition. J. Biol. Chem. 274, 11796–
11810 (1999).
51. R. Alvarez et al., Activation and selective inhibition of a cyclic AMP-specific phos-
phodiesterase, PDE-4D3. Mol. Pharmacol. 48, 616–622 (1995).
52. B. Buchholz, B. Teschemacher, G. Schley, H. Schillers, K. U. Eckardt, Formation of cysts
by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated
fluid secretion. J. Mol. Med. (Berl.) 89, 251–261 (2011).
53. S. Rees et al., Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J.
Am. Soc. Nephrol. 25, 232–237 (2014).
54. Q. Wang et al., Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth
in an orthologous mouse model of polycystic kidney disease. Kidney Int. 93, 403–415
(2018).
55. S. Terryn, A. Ho, R. Beauwens, O. Devuyst, Fluid transport and cystogenesis in auto-
somal dominant polycystic kidney disease. Biochim. Biophys. Acta 1812, 1314–1321
(2011).
56. E. Blanchard et al., Anchored PDE4 regulates chloride conductance in wild-type and
ΔF508-CFTR human airway epithelia. FASEB J. 28, 791–801 (2014).
57. J. A. Lambert et al., Cystic fibrosis transmembrane conductance regulator activation
by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am. J. Respir.
Cell Mol. Biol. 50, 549–558 (2014).
58. H. Li, I. A. Findlay, D. N. Sheppard, The relationship between cell proliferation,
Cl− secretion, and renal cyst growth: A study using CFTR inhibitors. Kidney Int. 66,
1926–1938 (2004).
59. B. Yang, N. D. Sonawane, D. Zhao, S. Somlo, A. S. Verkman, Small-molecule CFTR
inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 1300–
1310 (2008).
60. W. V. Breuer, E. Mack, A. Rothstein, Activation of K+ and Cl− channels by Ca2+ and
cyclic AMP in dissociated kidney epithelial (MDCK) cells. Pflugers Arch. 411, 450–455
(1988).
61. A. J. Streets et al., Parallel microarray profiling identifies ErbB4 as a determinant of
cyst growth in ADPKD and a prognostic biomarker for disease progression. Am. J.
Physiol. Renal. Physiol. 312, F577–F588 (2017).
62. C. D’Sa, L. M. Tolbert, M. Conti, R. S. Duman, Regulation of cAMP-specific phospho-
diesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical
neurons. J. Neurochem. 81, 745–757 (2002).
63. I. R. Le Jeune, M. Shepherd, G. Van Heeke, M. D. Houslay, I. P. Hall, Cyclic AMP-
dependent transcriptional up-regulation of phosphodiesterase 4D5 in human air-
way smooth muscle cells: Identification and characterization of a novel
PDE4D5 promoter. J. Biol. Chem. 277, 35980–35989 (2002).
64. Y. H. Choi et al., Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-
kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc.
Natl. Acad. Sci. U.S.A. 108, 10679–10684 (2011).
65. D. Willoughby et al., Dynamic regulation, desensitization, and cross-talk in discrete
subcellular microdomains during beta2-adrenoceptor and prostanoid receptor cAMP
signaling. J. Biol. Chem. 282, 34235–34249 (2007).
66. M. B. Beard et al., UCR1 and UCR2 domains unique to the cAMP-specific phospho-
diesterase family form a discrete module via electrostatic interactions. J. Biol. Chem.
275, 10349–10358 (2000).
67. A. B. Burgin et al., Design of phosphodiesterase 4D (PDE4D) allosteric modulators for
enhancing cognition with improved safety. Nat. Biotechnol. 28, 63–70 (2010).
68. J. P. Day et al., Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-
dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). J.
Med. Chem. 54, 3331–3347 (2011).
69. T. V. Masyuk, A. I. Masyuk, N. F. La Russo, Therapeutic targets in polycystic liver dis-
ease. Curr. Drug Targets 18, 950–957 (2017).
70. M. J. Lynch et al., RNA silencing identifies PDE4D5 as the functionally relevant cAMP
phosphodiesterase interacting with beta arrestin to control the protein kinase A/
AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK
in HEK293B2 cells. J. Biol. Chem. 280, 33178–33189 (2005).
71. C. S. Pinto et al., Phosphodiesterase isoform regulation of cell proliferation and fluid
secretion in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27,
1124–1134 (2016).
72. R. J. Marchmont, M. D. Houslay, A peripheral and an intrinsic enzyme constitute the
cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187,
381–392 (1980).
73. G. B. Bolger et al., Characterization of five different proteins produced by alterna-
tively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.
Biochem. J. 328, 539–548 (1997).
74. D. J. Henderson et al., The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated
in androgen-independent prostate cancer cells and mediates proliferation by com-
partmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. Br. J.
Cancer 110, 1278–1287 (2014).
75. R. Maitra, P. Sivashanmugam, K. Warner, A rapid membrane potential assay to
monitor CFTR function and inhibition. J. Biomol. Screen. 18, 1132–1137 (2013).
Omar et al. PNAS | July 2, 2019 | vol. 116 | no. 27 | 13329
B
IO
C
H
E
M
IS
T
R
Y
